The abstract is read at the publisher; the summary is JClub's.
In Pseudomonas aeruginosa isolates from 59 Australians with bronchiectasis (n=137), 75.9% showed resistance to at least one drug and 19.7% were multidrug-resistant.
- Why it matters: High prevalence of Pseudomonas aeruginosa in bronchiectasis is linked to worse outcomes, yet population genomics, AMR levels, persistence, and transmission patterns in Australians remain poorly defined.
- What they did: Isolates collected 2009–2025 underwent susceptibility testing to 11 antipseudomonal drugs plus whole-genome sequencing, comparative genomics, and in silico AMR determinant identification, integrated with 4,575 public bronchiectasis-derived genomes.
- The result: AMR was highest for ciprofloxacin (64.2%) and cefepime (44.5%) and lowest for colistin (0.7%) and piperacillin/tazobactam (8.8%); phylogenomics indicated within-host evolution and multi-lineage infections, with no geographic AMR clustering.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.